Literature DB >> 727897

Catecholamine metabolism in anorexia nervosa.

K A Halmi, H Dekirmenjian, J M Davis, R Casper, S Goldberg.   

Abstract

Urinary catecholamine levels were measured in 25 anorexia nervosa patients at the time when they were acutely ill with secondary depressive symptoms and again after treatment and weight gain to see whether changes in weight, activity levels, and symptoms of depression occurring during treatment might be associated with changes in urinary 3-methoxy-4-hydroxyphenylglycol (MHPG) concentrations. The latter was significantly lower in the acutely ill anorectics than in the control group. An increase in urinary MHPG concentration after treatment was significantly correlated with a decrease in depressive symptomatology. The increase in urinary MHPG level during treatment did not correlate significantly with change in patient's activity level. There seems to be a relationship between MHPG and the symptom of depression in a group of patients who do not carry a primary diagnosis of depression.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 727897     DOI: 10.1001/archpsyc.1978.01770280068007

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  4 in total

Review 1.  Neurobiology of aversive states.

Authors:  Erin N Umberg; Emmanuel N Pothos
Journal:  Physiol Behav       Date:  2011-05-01

Review 2.  Pharmacological manipulations in animal models of anorexia and binge eating in relation to humans.

Authors:  M A van Gestel; E Kostrzewa; R A H Adan; S K Janhunen
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

3.  Effects of long-term dietary restriction on cardiovascular function and plasma catecholamines in the rat.

Authors:  T Hilderman; K McKnight; K S Dhalla; H Rupp; N S Dhalla
Journal:  Cardiovasc Drugs Ther       Date:  1996-06       Impact factor: 3.727

4.  Lack of efficacy of psychological and pharmacological treatments of disorders of eating behavior: neurobiological background.

Authors:  Francesca Brambilla; Federico Amianto; Riccardo Dalle Grave; Secondo Fassino
Journal:  BMC Psychiatry       Date:  2014-12-24       Impact factor: 3.630

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.